Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

J Sawynok, MJ Esser, AR Reid - Journal of Psychiatry and …, 2001 - ncbi.nlm.nih.gov
… Data for amitriptyline, desipramine and fluoxetine are from Esser and Sawynok9 and Sawynok
… Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptiveaction of amitriptyline in the rat …

Memory T cells and vaccines

MT Esser, RD Marchese, LS Kierstead, LG Tussey… - Vaccine, 2003 - Elsevier
T lymphocytes play a central role in the generation of a protective immune response in many
microbial infections. After immunization, dendritic cells take up microbial antigens and traffic …

[HTML][HTML] Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

…, K Streicher, MN Pangalos, MT Esser - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

…, R Railkar, MT Esser, HL Sings, M Nelson… - … England Journal of …, 2007 - Mass Medical Soc
Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent
vaccine in preventing anogenital diseases associated with human papillomavirus (HPV…

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo …

…, R Railkar, FJ Taddeo, KU Jansen, MT Esser… - The lancet …, 2005 - thelancet.com
Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (…

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …

…, OM Bautista, MT Esser, HL Sings, M Nelson… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to infection
with human papillomavirus (HPV). These cancers are preceded by high-grade vulval …

[HTML][HTML] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

…, R Railkar, FJ Taddeo, J Bryan, MT Esser… - British Journal of …, 2006 - nature.com
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …

[HTML][HTML] Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

…, H Bright, YM Loo, PM McTamney, MT Esser… - Nature …, 2021 - nature.com
Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein
antigenic sites will inform the development of improved therapeutics. We determined the …

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

…, J Yu, L Lupinacci, R Railkar, R Marchese, MT Esser… - Vaccine, 2006 - Elsevier
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (…

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …

…, V Alagappan, MN Pangalos, MT Esser… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …